These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 22926520

  • 1. Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells.
    Chatain N, Ziegler P, Fahrenkamp D, Jost E, Moriggl R, Schmitz-Van de Leur H, Müller-Newen G.
    Oncogene; 2013 Aug 01; 32(31):3587-97. PubMed ID: 22926520
    [Abstract] [Full Text] [Related]

  • 2. Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction.
    Fahrenkamp D, de Leur HS, Küster A, Chatain N, Müller-Newen G.
    Cell Commun Signal; 2015 Feb 15; 13():10. PubMed ID: 25885255
    [Abstract] [Full Text] [Related]

  • 3. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE.
    Oncogene; 2002 Nov 21; 21(53):8075-88. PubMed ID: 12444544
    [Abstract] [Full Text] [Related]

  • 4. Tyrosine-phosphorylated STAT5 accumulates on podosomes in Hck-transformed fibroblasts and chronic myeloid leukemia cells.
    Poincloux R, Cougoule C, Daubon T, Maridonneau-Parini I, Le Cabec V.
    J Cell Physiol; 2007 Oct 21; 213(1):212-20. PubMed ID: 17503465
    [Abstract] [Full Text] [Related]

  • 5. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
    Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, Frost P, Ye F, Boschelli DH, Boschelli F.
    Cancer Res; 2003 Jan 15; 63(2):375-81. PubMed ID: 12543790
    [Abstract] [Full Text] [Related]

  • 6. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K.
    Cancer Res; 2002 Oct 15; 62(20):5761-9. PubMed ID: 12384536
    [Abstract] [Full Text] [Related]

  • 7. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 8. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
    Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, Hallek M, Van Etten RA, Li S.
    Nat Genet; 2004 May 01; 36(5):453-61. PubMed ID: 15098032
    [Abstract] [Full Text] [Related]

  • 9. An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259.
    Pene-Dumitrescu T, Peterson LF, Donato NJ, Smithgall TE.
    Oncogene; 2008 Nov 27; 27(56):7055-69. PubMed ID: 18794796
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
    Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R.
    Oncogene; 2002 Dec 12; 21(57):8804-16. PubMed ID: 12483533
    [Abstract] [Full Text] [Related]

  • 11. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
    Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee FY, Jove R.
    Mol Cancer Ther; 2007 Apr 12; 6(4):1400-5. PubMed ID: 17431118
    [Abstract] [Full Text] [Related]

  • 12. Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity.
    Jacobberger JW, Sramkoski RM, Frisa PS, Ye PP, Gottlieb MA, Hedley DW, Shankey TV, Smith BL, Paniagua M, Goolsby CL.
    Cytometry A; 2003 Aug 12; 54(2):75-88. PubMed ID: 12879454
    [Abstract] [Full Text] [Related]

  • 13. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
    Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M.
    Cancer Res; 1996 Aug 01; 56(15):3589-96. PubMed ID: 8758931
    [Abstract] [Full Text] [Related]

  • 14. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
    Gutiérrez-Castellanos S, Cruz M, Rabelo L, Godínez R, Reyes-Maldonado E, Riebeling-Navarro C.
    Eur J Haematol; 2004 Apr 01; 72(4):231-8. PubMed ID: 15089759
    [Abstract] [Full Text] [Related]

  • 15. Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.
    Peng Z, Luo HW, Yuan Y, Shi J, Huang SF, Li CL, Cao WX, Huang ZG, Feng WL.
    Oncol Rep; 2011 May 01; 25(5):1381-8. PubMed ID: 21369701
    [Abstract] [Full Text] [Related]

  • 16. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
    Konig H, Copland M, Chu S, Jove R, Holyoake TL, Bhatia R.
    Cancer Res; 2008 Dec 01; 68(23):9624-33. PubMed ID: 19047139
    [Abstract] [Full Text] [Related]

  • 17. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
    Zhou LL, Zhao Y, Ringrose A, DeGeer D, Kennah E, Lin AE, Sheng G, Li XJ, Turhan A, Jiang X.
    J Exp Med; 2008 Oct 27; 205(11):2657-71. PubMed ID: 18936234
    [Abstract] [Full Text] [Related]

  • 18. Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.
    Chu S, McDonald T, Bhatia R.
    Leukemia; 2010 Apr 27; 24(4):779-87. PubMed ID: 20200561
    [Abstract] [Full Text] [Related]

  • 19. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.
    Nieborowska-Skorska M, Slupianek A, Skorski T.
    Oncogene; 2000 Aug 24; 19(36):4117-24. PubMed ID: 10962572
    [Abstract] [Full Text] [Related]

  • 20. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.
    Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE, Skorski T.
    EMBO J; 2002 Nov 01; 21(21):5766-74. PubMed ID: 12411494
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.